Patients with MASLD have an increase in the production of CRP protein, oxidized LDL, and plasminogen activator inhibitor-1, as well as other inflammatory proteins mediated by IL-6 and TNF-α These factors in patients with MASLD are associated with an increased risk of CVD and vascular atherosclerosis [66,67]. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.